In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving -2.46% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.28% for ...

The model is built on CRISPR technology, a powerful gene editing tool used to edit genomes and develop therapies for genetic diseases. However, training to use this tool for designing experiments can ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

The CRISPR gene editing technology has transformed the research lab, and this powerful tool is now making its way into the clinic. So far, three different human diseases have been successfully treated ...

This makes the organs virus-free and less likely to trigger an immune response, improving their safety and durability.